Biostar Pharmaceuticals Inc
Biostar Pharmaceuticals, Inc. develops, manufactures, and markets pharmaceutical products for various diseases and conditions in the People's Republic of China. The company principally offers Xin Ao Xing Oleanolic Acid capsule, an OTC medicine for chronic hepatitis B. It also provides OTC products, such as Ganwang compound paracetamol and amantadine hydrochloride capsule for the relief of common … Read more
Biostar Pharmaceuticals Inc (BSPM) - Total Assets
Latest total assets as of September 2017: $41.43 Million USD
Based on the latest financial reports, Biostar Pharmaceuticals Inc (BSPM) holds total assets worth $41.43 Million USD as of September 2017.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Biostar Pharmaceuticals Inc - Total Assets Trend (2007–2016)
This chart illustrates how Biostar Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Biostar Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2016)
Biostar Pharmaceuticals Inc's total assets of $41.43 Million consist of 17.3% current assets and 82.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.4% |
| Accounts Receivable | $6.85 Million | 16.1% |
| Inventory | $166.56K | 0.4% |
| Property, Plant & Equipment | $5.87 Million | 13.8% |
| Intangible Assets | $5.61 Million | 13.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2016)
This chart illustrates how Biostar Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biostar Pharmaceuticals Inc's current assets represent 17.3% of total assets in 2016, a decrease from 32.8% in 2007.
- Cash Position: Cash and equivalents constituted 0.4% of total assets in 2016, down from 11.3% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, a decrease from 36.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 16.1% of total assets.
Biostar Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Biostar Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Biostar Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Biostar Pharmaceuticals Inc generates 0.06x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Biostar Pharmaceuticals Inc is currently not profitable relative to its asset base.
Biostar Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.19 | 1.12 | 3.30 |
| Quick Ratio | 0.16 | 1.05 | 3.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-4.28 Million | $ 759.72K | $ 29.27 Million |
Biostar Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Biostar Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.01 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -17.3% |
| Total Assets | $42.50 Million |
| Market Capitalization | $221.02 USD |
Valuation Analysis
Below Book Valuation: The market values Biostar Pharmaceuticals Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Biostar Pharmaceuticals Inc's assets decreased by 17.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Biostar Pharmaceuticals Inc (2007–2016)
The table below shows the annual total assets of Biostar Pharmaceuticals Inc from 2007 to 2016.
| Year | Total Assets | Change |
|---|---|---|
| 2016-12-31 | $42.50 Million | -17.25% |
| 2015-12-31 | $51.36 Million | -36.78% |
| 2014-12-31 | $81.25 Million | +20.25% |
| 2013-12-31 | $67.56 Million | -4.13% |
| 2012-12-31 | $70.48 Million | -15.15% |
| 2011-12-31 | $83.06 Million | +21.99% |
| 2010-12-31 | $68.09 Million | +44.83% |
| 2009-12-31 | $47.01 Million | +62.12% |
| 2008-12-31 | $29.00 Million | +43.22% |
| 2007-12-31 | $20.25 Million | -- |